Related Experiment Video
Updated: Mar 11, 2026
In Situ Detection of Autoreactive CD4 T Cells in Brain and Heart Using Major Histocompatibility Complex Class II Dextramers
Published on: August 1, 2014
ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired
Ilaria Mancini1, Barbara Ferrari2, Carla Valsecchi2
1Department of Pathophysiology and Transplantation, Università degli Studi di Milano, and Fondazione Luigi Villa, Milan, Italy.
Background:
Acquired thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy due to the development of autoantibodies against the VWF-cleaving protease ADAMTS13. ADAMTS13-specific circulating immune complexes (CICs) have been described in patients with acquired TTP, but their clinical relevance remained to be established. The aim of this study was to assess the association between ADAMTS13-specific CICs and ADAMTS13-related measurements, clinical and laboratory markers of disease severity, and occurrence of TTP relapse, in autoimmune TTP patients.
Material And Methods:
We measured ADAMTS13-specific CICs in 51 patients with severe ADAMTS13 deficiency and anti-ADAMTS13 autoantibodies, at the first episode of acquired TTP. The associations between ADAMTS13-specific CICs and the variables of interest were assessed by linear, logistic and Cox proportional hazard regression models, where appropriate.
Results:
The prevalence of ADAMTS13-specific CICs in patients experiencing the first TTP episode was 39% (95% confidence intervals [CI]: 26-52%). ADAMTS13-specific CICs were not associated neither with laboratory markers of disease severity, nor with patterns of clinical presentation. Conversely, among 45 survivors, a positive association was found between the presence of ADAMTS13-specific CICs and the risk of recurrence within 2years after the first TTP episode (adjusted hazard ratio, 3.4 [95% CI: 0.9 to 13.5]).
Conclusions:
ADAMTS13-specific CICs seem to be able to predict the recurrence of acute TTP episodes in the first 2years after disease onset. Therefore, their measurement might be used as a tool to stratify the risk of disease relapse, with potential influence on surveillance and therapeutic choices during remission phase.
Insights
ADAMTS13-specific circulating immune complexes (CICs) may predict thrombotic thrombocytopenic purpura (TTP) recurrence. Measuring ADAMTS13-specific CICs can help stratify relapse risk in TTP patients, guiding treatment and surveillance during remission.
Area of Science:
- Hematology
- Immunology
- Internal Medicine
Background:
- Acquired thrombotic thrombocytopenic purpura (TTP) is a rare microangiopathy caused by autoantibodies against ADAMTS13.
- ADAMTS13-specific circulating immune complexes (CICs) are found in TTP patients, but their clinical significance is unclear.
- Understanding the role of ADAMTS13-specific CICs is crucial for managing autoimmune TTP.
Purpose of the Study:
- To investigate the association between ADAMTS13-specific CICs and disease severity markers in TTP.
- To determine if ADAMTS13-specific CICs predict TTP relapse in autoimmune TTP patients.
- To evaluate the clinical relevance of ADAMTS13-specific CICs in TTP management.
Main Methods:
- ADAMTS13-specific CICs were measured in 51 patients with severe ADAMTS13 deficiency during their first TTP episode.
- Statistical models (linear, logistic, Cox regression) were used to assess associations.
- Outcomes included disease severity markers and TTP recurrence risk.
Main Results:
- ADAMTS13-specific CICs were present in 39% of first-episode TTP patients.
- No association was found between CICs and laboratory markers or clinical presentation of disease severity.
- Among survivors, ADAMTS13-specific CICs were associated with a 3.4-fold increased risk of TTP recurrence within 2 years.
Conclusions:
- ADAMTS13-specific CICs may serve as a predictive marker for TTP recurrence within the first two years post-onset.
- Measurement of ADAMTS13-specific CICs could aid in risk stratification for TTP relapse.
- This finding may influence surveillance strategies and therapeutic decisions during remission.
